Altimmune Inc
$ 3.41
-4.21%
21 Apr - close price
- Market Cap 443,659,000 USD
- Current Price $ 3.41
- High / Low $ 3.64 / 3.39
- Stock P/E N/A
- Book Value 2.03
- EPS -1.00
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -0.51 %
- 52 Week High 7.73
- 52 Week Low 2.87
About
Altimmune, Inc., a clinical-stage biopharmaceutical company, focuses on the development of intranasal vaccines, immunomodulatory therapies, and treatments for liver disease. The company is headquartered in Gaithersburg, Maryland.
Analyst Target Price
$18.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-26 | 2025-11-06 | 2025-08-12 | 2025-05-07 | 2025-03-25 | 2024-11-05 | 2024-08-08 | 2024-05-14 | 2024-03-27 | 2023-11-07 | 2023-08-10 | 2023-05-11 |
| Reported EPS | -0.27 | -0.21 | -0.27 | -0.26 | -0.33 | -0.3214 | -0.35 | -0.34 | -0.33 | -0.39 | -0.32 | -0.4 |
| Estimated EPS | -0.2491 | -0.27 | -0.31 | -0.3417 | -0.3351 | -0.35 | -0.34 | -0.37 | -0.43 | -0.42 | -0.46 | -0.48 |
| Surprise | -0.0209 | 0.06 | 0.04 | 0.0817 | 0.0051 | 0.0286 | -0.01 | 0.03 | 0.1 | 0.03 | 0.14 | 0.08 |
| Surprise Percentage | -8.3902% | 22.2222% | 12.9032% | 23.9099% | 1.5219% | 8.1714% | -2.9412% | 8.1081% | 23.2558% | 7.1429% | 30.4348% | 16.6667% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.25 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $2.91 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALT
2026-04-19 14:09:29
This report provides a comprehensive analysis of Altimmune (Nasdaq:ALT), a late clinical-stage biopharmaceutical company focused on liver diseases. It covers valuation, future growth prospects, past performance, financial health, and dividend information, highlighting that the stock is considered 87.3% undervalued by analysts. The company's lead product, pemvidutide, a dual GLP-1 and glucagon agonist, is central to its therapeutic strategy for conditions like MASH and alcohol-associated liver disease.
2026-04-17 12:40:04
Altimmune (NASDAQ: ALT) shareholders approved all proposals at their virtual Annual General Meeting on April 16, 2026. Key approvals include the election of nine directors, an increase in authorized common shares from 200 million to 400 million, and an expansion of the 2019 Employee Stock Purchase Plan reserve. These actions aim to strengthen the company's capital structure and governance.
2026-04-16 22:10:27
Altimmune shareholders have approved an amendment to double the authorized common stock from 200,000,000 to 400,000,000 shares. This decision was made at the 2026 Annual Meeting of Stockholders, alongside the election of directors, ratification of Ernst & Young LLP as the accounting firm, and approval of an amendment to the Employee Stock Purchase Plan. The company recently reported a larger-than-expected loss per share and significant revenue shortfall, but analysts have maintained varying ratings and price targets based on its therapeutic pipeline.
2026-04-16 22:09:33
Altimmune (ALT) stockholders re-elected all directors and approved several proposals at their 2026 annual meeting on April 16, 2026. These approvals included ratifying Ernst & Young LLP as auditor, endorsing the advisory say-on-pay vote for executive compensation, and increasing authorized common shares to 400 million, enhancing the company’s financial and compensation flexibility. Spark, TipRanks' AI Analyst, rated ALT as "Neutral" due to weak financial performance but noted positive Phase II results and FDA progress.
2026-04-16 21:09:33
Altimmune, Inc. shareholders have approved an amendment to increase the company's authorized common shares from 200,000,000 to 400,000,000, providing greater flexibility for future stock issuance. The approval occurred at the 2026 Annual Meeting, where shareholders also elected director nominees, ratified Ernst & Young LLP as the auditor, and approved an increase in the 2019 Employee Stock Purchase Plan reserve. These decisions were formally reported in an 8-K filing on April 16, 2026.
2026-04-16 21:09:33
Altimmune shareholders have approved an amendment to increase the number of authorized common stock from 200,000,000 to 400,000,000. This decision was made at the 2026 Annual Meeting of Stockholders, alongside the election of directors and ratification of auditors. The article also mentions recent analyst ratings for Altimmune, highlighting varying perspectives on its financial performance and pipeline.
